An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers


Full list of author information is available at the end of the article

© 2015 Blein et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abstract

Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers.

Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals.

Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk.

Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.

Introduction

Breast cancer is a multifactorial disease with genetic, lifestyle and environmental susceptibility factors. Approximately 15% to 20% of the familial aggregation of breast cancer is accounted for by mutations in high-penetrance susceptibility genes [1-3], such as BRCA1 and BRCA2. Pathogenic mutations in BRCA1 and BRCA2 confer lifetime breast cancer risk of 60% to 85% [4,5] and 40% to 85% [4,5], respectively. Other genomic variations (for example, in genes encoding proteins interacting with BRCA1 and BRCA2) have been identified as modifiers of breast cancer risk and increase or decrease the risk initially conferred by BRCA1 or BRCA2 mutation [6].

BRCA1 and BRCA2 are involved in DNA repair mechanisms, including double-strand break (DSB) repair by homologous recombination [7,8]. DSBs are considered to be among the most deleterious forms of DNA damage because the integrity of both DNA strands is compromised simultaneously. These breaks can lead to genomic instability resulting in translocations, deletions, duplications or mutations when not correctly repaired [9]. Reactive oxygen species (ROS) are one of the main causes of DSBs, along with exposure to ionizing radiation, various chemical agents and ultraviolet light [10]. ROS are naturally occurring chemical derivatives of metabolism. Elevated levels of ROS and downregulation of ROS scavengers and/or antioxidant enzymes can lead to oxidative stress, which is associated with a number of human diseases, including various cancers [11]. The electron transport chain process, which takes place in the mitochondria, generates the majority of ROS in human cells. Variations in the mitochondrial genome have been shown to be associated with metabolic phenotypes and
oxidative stress markers [12]. Mitochondrial dysfunction recently was shown to promote breast cancer cell migration and invasion through the accumulation of a transcription factor, hypoxia-inducible factor 1α, via increased production of ROS [13].

Human mitochondrial DNA (mtDNA) has undergone a large number of mutations that have segregated during evolution. Those changes are now used to define mitochondrial haplogroups. Some of these changes slightly modify metabolic performance and energy production; thus, not all haplogroups have identical metabolic capacities [14]. It has been hypothesized that the geographic distribution of mitochondrial haplogroups results from selection of metabolic capacities driven mainly by adaptation to climate and nutrition [15,16].

Mitochondrial haplogroups have been associated with diverse multifactorial diseases, such as Alzheimer’s disease [17], hypertrophic cardiomyopathy [18], retinal diseases [19] or age-related macular degeneration [20]. Variations in mtDNA have also been linked to several types of cancer, such as gastric cancer [21] or renal cell carcinoma [22]. Interestingly, variations in mtDNA have been linked to several types of female cancers, including endometrial [23], ovarian [24] and breast cancer [25,26]. A recent study underlined the possibility that mtDNA might be involved in the pathogenic and molecular mechanisms of familial breast cancer [27].

The Collaborative Oncological Gene-environment Study [28] (COGS) is a European project designed to improve understanding of genetic susceptibility to breast, ovarian and prostate cancer. This project involves several consortia: the Breast Cancer Association Consortium (BCAC) [29], the Ovarian Cancer Association Consortium [30], the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) [31] and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) [32]. CIMBA is a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers. As part of the COGS project, more than 200,000 single-nucleotide polymorphisms (SNPs) were genotyped for BRCA1 and BRCA2 female mutation carriers on the iCOGS chip, including 129 mitochondrial polymorphisms. The iCOGS chip is a custom Illumina™ Infinium genotyping array (Illumina, San Diego, CA, USA) designed to test, in a cost-effective manner, genetic variants related to breast, ovarian and prostate cancers.

In this study, we explored mitochondrial haplogroups as potential modifiers of breast cancer risk in women carrying pathogenic BRCA1 or BRCA2 mutations. Our study includes females diagnosed with breast cancer and unaffected carriers belonging to CIMBA. We used an original analytic phylogenetics-based approach implemented in a homemade algorithm and in the program ALTTree [33,34] to infer haplogroups and to detect associations between haplogroups and breast cancer risk.

**Methods**

**Ethics statement**

A signed informed written consent form was obtained from all participants. All contributing studies involved in CIMBA received approvals from the institutional review committees at their host institutions. Ethical committees that approved access to the data analyzed in this study are listed in Additional file 1.

**BRCA1 and BRCA2 mutation carriers**

Final analyses included 7,432 breast cancer cases and 7,104 unaffected BRCA1 mutation carriers, as well as 3,989 invasive breast cancer and 3,689 unaffected BRCA2 mutation carriers, all belonging to CIMBA. Supplementary specifications regarding inclusion profiles and studies belonging to CIMBA are available in the reports by Couch et al. [35] and Gaudet et al. [36]. All analyses were conducted separately on CIMBA BRCA1 and BRCA2 mutation carriers (abbreviated pop1 and pop2, respectively). Eligible female carriers were aged 18 years or older and had a pathogenic mutation in BRCA1 and/or BRCA2. Women with both BRCA1 and BRCA2 mutations were included in downstream analyses. Data were available for year of birth, age at study recruitment, age at cancer diagnosis, BRCA1 and BRCA2 mutation description and self-reported ethnicity. Women with ovarian cancer history were not excluded from analyses, and they represented 15% and 7% of BRCA1 and BRCA2 mutation carriers, respectively. Information regarding mastectomy was incomplete and was therefore not used as an inclusion or exclusion parameter.

**Genotyping and quality filtering**

Genotyping was conducted using the iCOGS custom Illumina Infinium array. Data from this array are available to the scientific community upon request. Please see [37] for more information. Genotypes were called using Illumina’s proprietary GenCall algorithm. Genotyping and quality filtering were described previously [35,36]. Initially, 129 mitochondrial SNPs were genotyped for both BRCA1 and BRCA2 mutation carriers. SNPs fulfilling the following criteria were excluded from downstream analyses: monoallelic SNPs (minor allele frequency = 0), SNPs with more than 5% data missing, annotated as triallelic, or having probes cross-matching with the nuclear genome. Heterozygous genotypes were removed from analyses, and we further filtered out SNPs having more than 5% of heterozygous calls to limit the potential for heteroplasmy affecting our results. We also did not retain SNPs representing private mutations. These mutations are rare, often restricted to a few families, and not sufficiently prevalent in the general population to be included in the reference
mitochondrial evolutionary tree (see below). This last step of filtration yielded 93 and 92 SNPs for the pop1 and pop2 analyses, respectively (see Additional file 2). Only individuals with fully defined haplotypes (that is, non-missing genotypes for the 93 and 92 SNPs selected for pop1 and pop2, respectively) were included in downstream analyses (14,536 and 7,678 individuals, respectively).

Mitochondrial genome evolution and haplogroup definition
Analyses were based on the theoretical reconstructed phylogenetic tree of the mitochondrial genome (mtTree) known as PhyloTree [38] (v.15). The mtTree is rooted by the Reconstructed Sapiens Reference Sequence (RSRS). RSRS has been identified as the most likely candidate to root the mtTree by refining human mitochondrial phylogeny by parsimony [39]. Each haplogroup in mtTree is defined by the set of mtDNA SNPs that have segregated in RSRS until today in the mitochondrial genome. Each haplogroup is fully characterized by the 16,569-bp sequence resulting from the application of all the substitutions that are encoded by the corresponding SNPs in the RSRS sequence.

Haplogroups imputation
The phylogenetic approach used to infer haplogroups is described in Figure 1. Mitochondrial genome sequences can be reconstructed at each node of mtTree, given the

![Figure 1](image.png)

**Figure 1** Simplified representation of the phylogenetic method used to infer haplogroups. (a) Full-length haplotypic sequences are reconstructed at each node of the reference tree. (b) Haplotypes are then restricted to available loci. Sequences of the same color are identical. (c) Unique short haplotypes are matched directly with the corresponding haplogroup. (d) Sequences that match with several haplogroups are associated with their most recent common ancestor haplogroup. RSRS, Reconstructed Sapiens Reference Sequence.
substitutions that have segregated in RSRS. Each haplogroup therefore has a corresponding full-length mitochondrial sequence. However, the full-length mitochondrial sequence is not available in the data, because the iCOGS platform captured only 93 and 92 SNPs for pop1 and pop2, respectively. Thus, for each of the 7,864 nodes of the phylogenetic tree, the corresponding short haplotype (that is, the full-length sequence restricted to available loci) was defined. Some of the short haplotypes are unique, and they can be matched with their corresponding haplogroup directly. However, most of the time, given the small number of SNPs analyzed, several haplogroups correspond to the same short haplotype. Consequently, a unique haplogroup cannot confidently be assigned to each short haplotype. Therefore, each short haplotype was assigned the most recent common ancestor of all the haplogroups that share the same short haplotype. Once this matching was done, short haplotypes were reconstructed in the same way for each individual in our dataset and were assigned the corresponding haplogroup. The accuracy of the method used was assessed by application to a set of 630 mtDNA sequences of known European and Caucasian haplogroups (see Additional file 3).

Association detection
This phylogenetic approach is based on the identification of subclades in the reference phylogenetic tree of the mitochondrial genome differentially enriched for cases and unaffected controls compared with neighboring subclades. We used ALTree [33,34] to perform association testing. ALTree—standing for Association detection and Localization of susceptibility sites using haplotype phylogenetic Trees—is an algorithm used to perform nested homogeneity tests to compare distributions of affected and unaffected individuals in the different clades of a given phylogenetic tree. The objective is to detect if some clades of a phylogenetic tree are more or less enriched in affected or unaffected individuals compared with the rest of the tree. There are as many tests performed as there are levels in the phylogenetic tree. The P-value at each level of the tree is obtained by a permutation procedure in which 1,000 permutations are performed. Individual labels (“affected” or “unaffected”) are permuted 1,000 times to see to what extent the observed distribution of affected or unaffected is different from a random distribution. A procedure to correct for multiple testing adapted to nested tests [40] is implemented in ALTree. The objective of ALTree is to detect an enrichment difference at the level of the whole tree. To conserve computational time and resources, only the most significant P-value obtained for all tests performed on one tree is corrected.

Handling genetic dependency
ALTtree is used to perform homogeneity tests to detect differences in enrichment or depletion of affected or unaffected individuals between clades in the phylogenetic tree. This kind of test can be performed only on independent data. However, because some individuals in the CIMBA dataset belong to the same family, we constructed datasets with genetically independent data by randomly selecting one individual from among all those belonging to the same family and sharing the same short haplotype. To take into account the full variability of our data, we resampled 1,000 times. The results of the analysis pipeline are obtained for each resampling independently and then averaged over the 1,000 resamplings to obtain final results.

Character reconstruction at ancestral nodes
Before the ALTree localization algorithm was launched, ancestral sequences were reconstructed at each internal tree node; that is, short haplotypes were inferred with maximum likelihood at all nodes that were not leaves. We used the software PAML [41] to perform the reconstruction at ancestral nodes using a maximum likelihood method. The phylogeny model used was the general time-reversible model (either GTR or REV).

Localization of susceptibility sites
ALTtree also includes an algorithm used to identify which sites are the most likely ones to be involved in the association detected. For each short haplotype observed, the ALTtree add-on altree-add-S adds to the short haplotype sequence a supplementary character called S, which represents the disease status associated with this short haplotype. Are individuals carrying this short haplotype more often affected or unaffected? S is calculated based on the affected and unaffected counts, the relative proportion of affected and unaffected in the whole dataset, and sensibility parameter e. e was set to its default value, which is 1. After S character computation, haplotypes including character S are reconstructed at ancestral nodes. Susceptibility site localization is achieved with ALTtree by computing a correlated evolution index calculated between each change of each site and the changes of the character S in the two possible directions of change. The sites whose evolution are the most correlated with the character S are the most likely susceptibility sites.

Selected subclades
The analyses were carried out on the full evolutionary tree. However, the more haplogroups there are at each level, the less statistical power homogeneity tests have. Therefore, analyses were also applied to subclades extracted from the tree. Subclades were defined using counts of individuals in each haplogroup of the clade to maximize statistical power. The chosen subclades
and corresponding affected and unaffected counts are presented in Table 2.

**Statistical analysis**

We quantified the effect associated with enrichment discovered by applying ALTtree by building a weighted Cox regression in which the outcome variable is the status (affected or non-affected) and the explicative variable is the inferred haplogroup. Analyses were stratified by country. Data were restricted to the clades of interest. The uncertainty in haplogroup inference was not taken into account in the model. The weighting method used takes into account breast cancer incidence rate as a function of age [42] and the gene containing the observed pathogenic mutation (that is, \textit{BRCA1} or \textit{BRCA2}). Familial dependency was handled by using a robust sandwich estimate of variance (R package \textit{survival}, \texttt{cluster()} function).

**Results**

**Haplogroup imputation**
In Additional file 4, absolute and relative frequencies are recapitulated for each haplogroup imputed in \textit{BRCA1} and \textit{BRCA2} mutation carriers. For \textit{BRCA1} mutation carriers, we reconstructed 489 distinct short haplotypes of 93 loci from the genotypes data. Only 162 of those 489 short haplotypes matched theoretical haplotypes reconstructed in the reference mitochondrial evolutionary tree. These 162 haplotypes represented 13,315 of 14,536 individuals. Thus, 91.6\% of \textit{BRCA1} mutation carriers were successfully assigned a haplogroup. For \textit{BRCA2} mutation carriers, we reconstructed 350 distinct short haplotypes of 92 loci from our genotype data. Only 139 of those 350 short haplotypes matched theoretical haplotypes reconstructed in the reference mitochondrial evolutionary tree. These 139 haplotypes represented 6,996 of 7,678 individuals. Thus, 91.1\% of \textit{BRCA2} mutation carriers were successfully assigned a haplogroup.

The accuracy of the main haplogroup inference method used was estimated at 82\% and reached 100\% for haplogroups I, J, K, T, U, W and X. Given the set of SNPs we disposed of, our method has difficulty differentiating between H and V haplogroups (see Additional file 3).

**Association results**

For both populations of \textit{BRCA1} or \textit{BRCA2} mutation carriers, as well as for the full tree as for all selected subclades (see Table 1), we extracted the mean corrected \textit{P}-values for association testing over all resamplings performed (see Table 2). The only corrected \textit{P}-value that remained significant was that obtained for subclade T (abbreviated T*) in the population of individuals of \textit{BRCA2} mutation carriers (\(P = 0.04\)).

The phylogenetic tree of subclade T (see Figure 2a) contains only three levels; thus, only three tests were performed within this clade. Raw \textit{P}-values were examined to determine at which level of the tree ALTtree detects a difference of enrichment in affected or unaffected individuals (see Table 3). Only the \textit{P}-value associated with the test performed at the first level of the tree is significant. We looked more closely at the mean frequencies of affected and unaffected individuals in the tree at this level (see Figure 2b). In the T1a1 subclade, the mean count of affected and unaffected are 32 and 47, respectively. In the T2* subclade, we observed, on average, 217 and 148 affected and unaffected individuals, respectively, whereas in the T subclade, we observed, on average, 13 and 11 affected and unaffected individuals, respectively. The ranges observed for each of these values over the 1,000 resamplings are represented in Figure 2b. On the basis of these observations, we conclude that subclade T1a1 is depleted in affected carriers compared with the neighboring subclades T and T2.

<table>
<thead>
<tr>
<th>Table 1 Counts of participants in selected subclades</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subclade</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>U8</td>
</tr>
<tr>
<td>T</td>
</tr>
<tr>
<td>J</td>
</tr>
<tr>
<td>J1</td>
</tr>
<tr>
<td>H</td>
</tr>
<tr>
<td>H1</td>
</tr>
<tr>
<td>U5</td>
</tr>
<tr>
<td>X1'T3</td>
</tr>
<tr>
<td>Kl1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2 Mean corrected \textit{P}-values for association testing with ALTtree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subclade</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Full</td>
</tr>
<tr>
<td>U8</td>
</tr>
<tr>
<td>T</td>
</tr>
<tr>
<td>J</td>
</tr>
<tr>
<td>J1</td>
</tr>
<tr>
<td>H</td>
</tr>
<tr>
<td>H1</td>
</tr>
<tr>
<td>U5</td>
</tr>
<tr>
<td>X1’T3</td>
</tr>
<tr>
<td>Kl1</td>
</tr>
</tbody>
</table>

*pop1, \textit{BRCA1} mutation carrier; pop2, \textit{BRCA2} mutation carrier. Bold indicates a significant \textit{P}-value.
Localization results
We performed a localization analysis with ALTTree. The correlated evolution index for all non-monomorphic sites observed in short haplotype sequences of subclade T are displayed in Additional file 5. The higher the correlated evolution index, the more likely it is that corresponding sites will be involved in the observed association. Three short haplotype sites numbered 44, 57 and 72 and corresponding to SNPs T988C, G11812A/rs4154217 and G13708A/rs28359178, respectively, clearly distinguish themselves, with correlation index values of 0.390, 0.324 and 0.318, respectively, whereas the correlation index values of all other sites ranged from −0.270 to −0.101. Table 4 shows the details for these three loci.

Effect quantification
The ALTTree method is able to detect an association, but cannot to quantify the associated effect. We estimated the risk of breast cancer for individuals with the T1a1 haplogroup compared with individuals with another T subclade haplogroup in the population of BRCA2 mutation carriers using a more classical statistical method, a weighted Cox regression. We found a breast cancer HR of 0.55 (95% CI, 0.34 to 0.88; \( P = 0.014 \)). We also tested haplogroup T1a1 and compared it with other T* haplogroups and the H haplogroup (the main haplogroup in the general population), and we found a breast cancer HR of 0.62 (95% CI, 0.40 to 0.95; \( P = 0.03 \)).

Discussion
We employed an original phylogenetic analytic method, coupled with more classical molecular epidemiologic analyses, to detect mitochondrial haplogroups differentially enriched for affected BRCA1/2 mutation carriers. We successfully inferred haplogroups for more than 90% of individuals in our dataset. After haplogroup imputation, the ALTTree method identified T1a1 in the T clade as differentially enriched in affected BRCA2 mutation carriers, whereas no enrichment difference was found for BRCA1 mutation carriers. The T subclade is present in 4% of African populations compared with 11% in Caucasian and Eastern European populations [43]. In our data, the T subclade represented 9.34% of BRCA1 mutation carriers and 9.30% of BRCA2 carriers. The ALTTree method also identified three potential breast cancer susceptibility loci in mtDNA. The main goals of using the phylogenetic method we used were to improve statistical power by regrouping subclades according to genetic considerations, to limit the number of tests performed and to precisely quantify this number. ALTTree identified three SNPs of interest. Whereas the association we observed could possibly be driven by a single SNP, no difference was observed between multivariate and univariate cox models including the three SNPs identified by ALTTree (data not shown).

In this study, we investigated to what extent mtDNA variability modified breast cancer risk in individuals

Table 3 Non-corrected \( P \)-values by level of phylogenetic tree for subclade T in BRCA2 mutation carriers

<table>
<thead>
<tr>
<th>Level</th>
<th>Degrees of freedom</th>
<th>Mean of non-corrected ( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>0.02141039</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>0.14355900</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>0.22249700</td>
</tr>
</tbody>
</table>

Figure 2 Phylogenetic tree of subclade T tested for association with ALTTree. (a) Phylogenetic tree of subclade T with all observed haplogroups. A homogeneity test is performed at each level of the tree. (b) First level of the phylogenetic tree of subclade T. Averaged counts, ranges and proportions of affected and unaffected observed in resamplings are indicated below each subclade. T2* represents the entire T2 subclade.
Table 4 Description of loci identified as potential susceptibility sites by ALTReea

<table>
<thead>
<tr>
<th>Site</th>
<th>SNP name</th>
<th>Position</th>
<th>Direction of change</th>
<th>Correlated evolution index</th>
<th>Major allele</th>
<th>Minor allele</th>
<th>MAF in pop2</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
<td>MitoT99000C</td>
<td>9,899</td>
<td>T → C</td>
<td>0.390</td>
<td>T</td>
<td>C</td>
<td>0.016</td>
</tr>
<tr>
<td>57</td>
<td>rs41544217</td>
<td>11,812</td>
<td>G → A</td>
<td>0.324</td>
<td>A</td>
<td>G</td>
<td>0.071</td>
</tr>
<tr>
<td>72</td>
<td>rs28359178</td>
<td>13,708</td>
<td>G → A</td>
<td>0.318</td>
<td>G</td>
<td>A</td>
<td>0.111</td>
</tr>
</tbody>
</table>

aMAF, Mean allele frequency; pop2, BRCA2 mutation carrier.

carrying pathogenic mutations in BRCA1/2. A large proportion of breast cancer heritability still remains unexplained today [44]. Different methods exist to study genomic susceptibility to a disease, such as linkage analyses (which identified the BRCA1 and BRCA2 susceptibility genes) or genome-wide association studies (GWASs). However, classical linkage analysis cannot be applied to the haploid mitochondrial genome. Furthermore, commercial GWAS chips available do not adequately capture the majority of mtDNA SNPs. A non-genome-wide and mtDNA-focused approach was required to explore how mtDNA variability influences breast cancer risk. Here we have shown that BRCA2 mutation carriers with the subclade T1a1 have between 30% and 50% less risk of breast cancer than those with other clades, which, if validated, is a clinically meaningful risk reduction and may influence the choice of risk management strategies.

The association we observed among BRCA2, but not BRCA1, mutation carriers may reveal a functional alteration that would be specific to mechanisms involving BRCA2-related breast cancer. Today, it is established that BRCA1- and BRCA2-associated breast cancers are not phenotypically identical. These two types of tumors do not harbor the same gene expression profiles or copy number alterations [45]. Breast cancer risk modifiers in BRCA1/2 mutation carriers have already been identified [46]. However, most of them are specific from one or the other type of mutation carried [47]. It is therefore not surprising that this observation is observed in BRCA2 mutation carriers only.

Our inability to assign haplogroups to 9% of study participants could have three main explanations. First, given the high mutation rate in the mitochondrial genome, observed combinations of mtDNA SNPs might have appeared relatively recently in the general population, and the corresponding haplotypes might not yet be incorporated into PhyloTree. Second, only one genotyping error could lead to chimeric haplotypes that do not exist, although, given the quality of our genotyping data, this is unlikely. Third, the mitochondrial reference evolutionary tree PhyloTree is based on phylogeny reconstruction by parsimony, and, for some subclades, it might be suboptimal, especially for haplogroups relying on few mitochondrial sequences, as is the case for African haplogroups [48]. In cases of uncertainty, the choice we made to assign the most recent common ancestor to the studied haplotype enabled us to improve statistical power without introducing a bias in the detected association. For the association detected between T, T1* and T2* subclades, the haplogroup inference method used did not bias the counts of affected and unaffected individuals in these subclades. More details are presented in Additional file 6. Furthermore, on the basis of the haplogroup inference with our method of 630 European and Caucasian mtDNA sequences whose haplogroup is known, we successfully assigned the correct main haplogroup and subhaplogroup of 100% of sequences belonging to T, T2* and T1a1* haplogroups.

We quantified the effect corresponding to the detected association by using a more classical approach. We built a weighted Cox regression including inferred haplogroup as an explicative variable. However, the uncertainty in haplogroup inference was not taken into account in this model. Nevertheless, based on haplogroup assignment and regrouping performed in clade T, affected and unaffected counts of individuals in this clade were not biased.

With only 129 loci genotyped over the 16,569 nucleotides composing the mitochondrial genome, we certainly did not explore the full variability of mitochondrial haplotypes. A characterization of individual mitochondrial genomes would require more complete data acquisition methods to be used, such as next-generation sequencing. However, next-generation sequencing has its own limits and challenges, because some regions of the mitochondrial genome are not easily mappable, owing to a high homology with the nuclear genome, among other factors, and important bioinformatics treatment is necessary to overcome sequencing technology biases. Finally, even for a relatively short genome of “only” 16,569 bp, mtDNA sequencing of more than 20,000 individuals would represent a major increase in cost relative to genotyping 129 SNPs.

ALTRea identified T9899C, G11812A/rs41544217 and G13708A/rs28359178 as three potential susceptibility sites for the discovered association (see Additional file 7). These three SNPs are located in the coding part of genes MT-CO3, MT-ND4 and MT-ND5, respectively. When looking at PhyloTree, T9899C seems to be involved in T1 subclade definition, whereas G13708A and A11812G are involved in T2 subclade definition. Whereas T98899C and
G11821/rs41544217 are synonymous SNPs, G10398A leads to a change of amino acid in the final protein (from alanine to threonine). These two synonymous SNPs have never been described in a disease context in the literature. G13708A is also known for being a secondary mutation for Leber’s hereditary optic neuropathy (LHON) and multiple sclerosis [49]. Although the role of secondary mutations in LHON is still controversial, G13708A could be associated with impairment of the respiratory chain in this pathology. G13708A has also been described as a somatic mutation in a breast cancer tumor, whereas it was not present in adjacent normal tissue or in blood leukocytes [50]. A high proportion of mitochondrial somatic tumor-specific variants are also known mtDNA SNPs, which is consistent with the hypothesis that tumor cells are prone to acquire the same mutations that segregate into mtDNA by selective adaptation when humans migrated out of Africa and confronted new environments [51]. Interestingly, the germine variant G13708A has already been shown to be inversely associated with familial breast cancer risk (with the same direction of the association), with a breast cancer odds ratio of 0.47 (95% CI, 0.24 to 0.92) [52]. None of these SNPs have been described in the context of ovarian cancer.

The corrected P-value obtained using ALTTree in studying clade T is 0.02, which is not highly significant. A replication step should be performed to validate these results. However, it will be difficult to include enough women in this replication step, given the specific profile studied here. In fact, the estimations of BRCA2 pathogenic mutations in the general population range from 0.068% [5] to 0.69% [53]. T1a1 represents only a small percentage of European haplogroups (from 1% to 2%). The number of women who have this association is therefore low. However, women carrying such mutations are confronted with drastic choices regarding the prevention of breast cancer, notably prophylactic mastectomy or complete hysterectomy. If breast cancer risk is really reduced by a factor of 2 for women with T1a1, this could be an important fact to take into account for breast cancer prevention.

Conclusions

This study and our results suggest that mitochondrial haplogroup T1a1 may modify the individual breast cancer risk in BRCA2 mutation carriers. For now, this observation cannot be extended to the general population. Further investigation of the biological mechanism behind the associations we observed may further reinforce the hypothesis that the mitochondrial genome is influential in breast cancer risk, particularly among carriers of BRCA2 mutations, and, if validated, is of a level to influence cancer risk management choices.
members of and participants in the Ontario Familial Breast Cancer Registry for their contributions to the study; Vilius Rudatis, Laimonas Grivičkis; Drs Janis Egilis, Anna Klito and Aivars Stengrevics; the families who contribute to the BRCA-gene mutations and breast cancer in South African women (BMBSA) study; Chun Ding and Linda Steel; Alicia Barroso, Rosario Alonso, Guillermo Pita, Alessandra Viel and Lara della Puppa of the Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy; Laura Papi of the University of Florence, Florence, Italy; Monica Barile of the Istituto Erupeo di Oncologia, Milan, Italy; Liliana Vareoso of the IRCCS AOI San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; Stefania Tommasi, Brunella Pilato and Rossana Lambro of the Istituto Nazionale Tumori “Giovanni Paolo II” – Bari, Italy; Aline Martayan of the Istituto Nazionale Tumori Regina Bena, Rome, Italy; Maria Grazia Tablitti of the Ospedale di Circolo Università dell’Insubria, Varese, Italy; and the personnel of the CogenTec Cancer Genetic Test Laboratory, Milan, Italy.

**Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBREC)** Collaborating Centers: coordinating center, Cambridge, UK: Debra Frost, Steve Ellis, Elena Fineberg and Radka Platte; North of Scotland Regional Genetics Services, UK: Sonja Lane, Charles Atkins, Stuart Michie, and Northern Ireland Regional Genetics Service, Belfast, UK: Patrick Morrison and Lisa Jeffers; West Midlands Regional Clinical Genetic Service, Birmingham, UK: Trevor Cole, Kari-ren Ong and Jonathan Hoffman; South West Regional Genetics Service, Bristol, UK: Alan Donaldson and Margaret James; East Anglian Regional Genetics Service, Cambridge, UK: Marc Tischkowitz, Joan Paterson and Amy Taylor; Medical Genetic Services, Cardiff, UK: Alexandra Murray, Mark T Rogers and Emma McCann; St James’s Hospital, Dublin, and National Centre for Medical Genetic, Dublin, Ireland: M John Kennedy and David Barton; South East of Scotland Regional Genetics Service, Edinburgh, UK: Mary Porteous and Sarah Drummond; Peninsula Clinical Genetics Service, Exeter, UK: Carole Brewer, Emma Kivuva, Annie Searle, Selina Goodman and Kathryn Hill; West of Scotland Regional Genetics Service, Glasgow, UK: Rosemary Davidson, Victoria Murray, Nadia Bradshaw, Lesley Snaddon, Mark Longmuir, Catherine Watt, Sarah Gibson, Eishila Haque, Ed Tobias and Alexia Duncan; South East Thames Regional Genetics Service, Guy’s Hospital London: Louise Izatt, Chris Jacobs and Caroline Langman; North West Thames Regional Genetics Service, Harrow, UK: Huw Dorkins; Leicestershire Clinical Genetics Service, Leicester, UK: Julian Banwell; Yorkshire Regional Genetics Service, Leeds, UK: Julian Adlaid and Gemma Serra-Fellu; Cheshire & Merseyside Clinical Genetics Service, Liverpool, UK: Ian Ellis and Catherine Houghton; Manchester Regional Genetic Service, Manchester, UK: D Gareth Evans, Fiona Laloo and Jane Taylor. North East Thames Regional Genetics Service, NE Thames, London: Lucy Side, Alison Male and Cheryl Berlin; Nottingham Centre for Medical Genetics, Nottingham, UK: Jacqueline Eason and Rebecca Collier; Northern Clinical Genetics Service, Newcastle, UK: Fiona Douglas, Oonagh Claber and Irene Jobson; Oxford Regional Genetics Service, Oxford, UK: Lisa Walker, Diane McLeod, Dorothy Halliday, Sarah Durell and Barbara Stayner; the Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London: Ros Eele, Susan Shanahan, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Elizabeth Page, Audrey Ardern-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Emma Killick, Sue Martin, Gillian Rea and Anjana Kulkarni; North Trent Clinical Genetics Service, Sheffield, UK: Jackie Cook, Oliver Quarrler and Cathryn Bardsley; South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizze Winchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard and Anna Lehmann; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK: Diana Etchells, Amiee Linnane, Josh, Gillian Crawford, Donna Midlars and Sarah Smalley; and JolEllen Weaver and Dr Betsy Bove for their technical support.

**Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO)** study: National Cancer Genetics Network UNICANCER Genetic Group, France; GEMO Collaborating Centers: coordinating centers, Unité Mixte de Génétique Constitutionnelle des Cancers Férducts, Hospices Civils de Lyon – Centre Léon Bérard, and équipe Génétique du cancer du sein; Centre de Recherche en Cancérologie de Lyon: Olga Sinilnikova, Sylvie Mazoyer, Francesca Damilola, Laure Barjhoux, Carole Vialle, Claire Aguirre and Mélanie Léone; and Service de Génétique Oncologique, Institut Curie, Paris, France: Marie-Agnès Collonge-Rame and Alexandre Damette, Creighton University, Omaha, USA: Terry L Lynch and Carole L Snyder; the technical support of Ilse Coene en Brecht Crome, and the investigators of the Australia New Zealand Gynaecological Oncology Group (ANZOGOG). We acknowledge Alícia Tosar for her technical assistance; Taru A Musanen, Drs Carl Blomqvist and Kimmar Aalto, and registered nurses Ija Eirkkiä and Virpi Palaio for their help with the Helsinki Breast Cancer Study (HEBCS) data and samples.

**The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HERBON) collaborating centers:** Netherlands Cancer Institute, Amsterdam: MA Rookus, FBL Hogervorst, VE van Leeuwen, S Verhoeef, MK Schmidt, J de Lange and R Wijnhagen; Erasmus Medical Center, Rotterdam, the Netherlands: JIM Collee, AMW van den Ouweland, MH Hoongen, C Seynena, CHM van de Weijer and IM Obdeijn; Leiden University Medical Centre, Leiden, the Netherlands: CJ van Asperen, JT Wijn, RAEV Tollenaar, PD Veelv and TCTEF van Cronenburg; Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands: CM Kets and AR Mensenkamp; University Medical Center Utrecht, Utrecht, the Netherlands: MGEM Aussem and RB van der Luit; Amsterdam Medical Centre, Amsterdam: CM Aalfs and TAM van Os; VU University Medical Center, Amsterdam: JP Gille, Q Wautz and HEI Meijs-Hoibe; University Hospital Maastricht, Maastricht, the Netherlands: BB Gómez-Garcia and MJ Blok; University Medical Centre Groningen, Groningen, the Netherlands: JC Oosterwijk, AH van der Hout, MJ Mousts and GH de Bock; The Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, the Netherlands: HF Vazen; The Netherlands Cancer Registry; S Siedling, The Dutch Pathology Registry (PALGA): LH Overbeek; Hong Kong Sanatorium & Hospital for their continual support; Janos Papp, Tibor Vaszkó, Aniko Bozsik, Timea Pocza, Judit Franko, Maria Balogh, Drs Ana Peixoto, Catarina Santos, Patrícia Rocha and Pedro Pinto for their skillful contributions to the study; Heather Thorne, Eveline Niedermayer, all the iConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the clinical follow-up study (which has received funding from the National Health and Medical Research Council (NHMRC), the National Breast Cancer Foundation, Cancer Australia and the National Institutes of Health (Bethesda, MD, USA)) for their contributions to this resource; and the many families who contribute to iConFab; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (iConFab); Lenia Foretova and Eva Machackova (Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, and the Medical Faculty, Masaryk University, Brno, France: Agnès Hardouin and Pascaline Berthet; Institut Paoli Calmettes, Marseille, France: Hayag Sobol, Violaine Bourdon, Tetsuro Noguchi, Audrey Remieniers and François Esiring; Centre Hospitalier Régional Universitaire Arnaud-de-Villeneuve, Montpellier, France: Isabelle Couperie and Pascal Pugl; Centre Oscar Lambret, Lille, France: Jean-Philippe Peyrat, Joëlle Fournier, François Révillon, Philippe Vennin and Claude Adenis; Hospital René Huguenin, Institut Curie, Saint-Cloud, France: Etiene Bouleau, Rosette Lidereau, Liliane Demange and Catherine Nougues; Centre Paul Strauss, Strasbourg, France: Danièle Müller and Jean-Pierre Fricker; Institut Bergonie, Bordeaux, France: Emmanuelle Barouk-Simonet, François Bonnet, Virginie Bubien, Nicolas Sevnet and Michel Longy; Institut Claudius Regaud, Toulouse, France: Christinne Toulou, Rosine Guimbaud, Grazia Borgia, Marie-Christine Dehollain, Centre Hospitalier Universitaire de Grenoble, Grenoble, France: Dominique Leroux, Hélène Dreyfus, Christine Rebischung and Magalie Peysselon; Centre Hospitalier Universitaire de Dijon, Dijon, France: Fanny Corin and Laurence Faivre; Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France: Fabienne Prieur, Marine Lebrun and Caroline Kientz; Hôpital Dieu Centre Hospitalier, Chambéry, France: Sandra Fert Ferrer; Centre-Antoine Lacassagne, Nice, France: Marc Fréinay; Centre Hospitalier Universitaire de Limoges, Limoges, France: Cédric Vaissier and Hélène Simic; Centre Hospitalier Universitaire de Nantes, Nantes, France: Capucine Delnatte; Centre Hospitalier Universitaire de Bretonneau, Tours, France: Isabelle Mortemousquie; Groupe Hospitalier Pitié-Salpêtrière, Paris: Florence Coulet, Chrystelle Colas and Florent Soubrier; Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France: Johanna Sokolowska and Myriam Bronner; Centre Hospitalier Régional Universitaire de Wallonië, Charleroi, Belgium: Francine Lewi, France: Marie-Agnès Collonge-Rame and Alexandre Damette, Creighton University, Omaha, USA: HE: Terry L Lynch and Carole L Snyder; the technical support of Ilse Coene en Brecht Crome; and the investigators of the Australia New Zealand Gynaecological Oncology Group (ANZOGOG).
Czech Republic); Michal Zikan, Petr Pohrlreich and Ždenek Klebl (Oncogenecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic); Anne Lincoln and Lauren Jacobs; the National Israeli Cancer Control Center (NICC) National Familial Cancer Consultation Service team led by Sara Dishon; the laboratory team led by Dr Flavio Lejbkowicz; and the research field operations team led by Mia Pinchey; members and participants in the Ontario Cancer Genetics Network for their contributions to the study. Leigha Senter, Kevin Sweet, Caroline Cavene and Michelle O’Conor were instrumental in accrual of study participants; ascertainment of medical records and database management; The Ohio State University Human Genetics Sample Bank; the Merav Breast Center team at the Sheba Medical Center, Àke Borg, Håkan Olsson, Helena Jernström, Karin Henrisson, Kajta Harbst, Maria Soller and UK Kirofferson; Sahlgrensa University Hospital, Gothenburg, Sweden; Anna Øverholm, Margareta Nordling, Per Karlsson and Zakaria Einberg; Stockholm and Karolinska University Hospital, Stockholm; Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Britta Arver, Gisela Barbany Bustriza and Johanna Rantala; Umeå University Hospital, Umeå, Sweden; Beatrice Melin, Christina Edwinsdotter Ardor and Monica Emanuelsenius; Uppsala University, Uppsala, Sweden; Charlotte Hammarström, Karl Jonas Hellström, Per Nilsson, and Roland Rosenquist; Linköping University Hospital, Linköping, Sweden; Marie Stenmark-Aksamül and Sigrun Liedgren; Cecilia Zvocer, Qun Niu, and physicians, genetic counselors, research nurses and staff of the Comprehensive Cancer Risk and Prevention Clinic of University of Chicago, Chicago, IL, USA, for their contributions to this resource; Joyce Seldon, MSGC, and Lorna Kwan, MPH; Dr Robert Nusbaum and the following genetic counselors: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Bianco and Peggy Conrad; Salina Chan; Paul DP Fabrao, Simon Gayther, Susan Ramus, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions to the UK Familial Ovarian Cancer Registry (UKFCR); Geoffrey Lindeman, Marion Harris, Martin Delatycki of the Victorian Familial Cancer Trials Group; and Sarah Sawyer, Rebecca Driessen and Ella Thompson.

**Funding**

**Higher-level funding:** The COGS project is funded through a European Commission Seventh Framework Program grant (agreement number 223175: HEALTH-F2-2009-223175). The CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. SH is supported by a National Health and Medical Research Council (NHMRC) program grant (to GCT).

**Individual researcher support:** ACA is a Cancer Research UK Senior Cancer Research Fellow (C12292/A11174). DFE is a Principal Research Fellow of Cancer Research UK GC, MCS and IC are supported by the National Health and Medical Research Council (NHMRC). BK holds an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). MHG and PLM were supported by funding from the Intramural Research Program of the National Cancer Institute, National Institutes of Health. OIO is an American Cancer Society Clinical Research Professor. JS is Chairholder of the Canada Institutional Strategic Project 5×1000 (to SM); the Italian Association for Education and Lifelong Learning operational program. DGE and FL are supported by GOA grant BOF/10/GOA/019 (Ghent University) and spearhead funding of Ghent University Hospital; the Gynecologic Oncology Group (GOG) was supported by National Cancer Institute grants to the GOG Administrative Office and Tissue Bank (grant CA 27469), the GOG Statistical and Data Center (grant CA 37517) and GOG’s Cancer Prevention and Control Committee (grant CA 101165); HCSC was supported by grants RD12/00369/00016 and 12/00339 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain, partially supported by European Regional Development Fund (Fonds européen de développement régional (FEDER)) funds; the Helsinki Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation; HEBON is supported by grants RD12/00369/00016 and 12/00339 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain, partially supported by European Regional Development Fund (Fonds européen de développement régional (FEDER)) funds; the Helsinki Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation; HEBON is supported by grants RD12/00369/00016 and 12/00339 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain, partially supported by European Regional Development Fund (Fonds européen de développement régional (FEDER)) funds; the Helsinki Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation; HEBON is supported by grants RD12/00369/00016 and 12/00339 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain, partially supported by European Regional Development Fund (Fonds européen de développement régional (FEDER)) funds.
Carlos III (ISCIII); Catalan Health Institute; and Autonomous Government of Catalonia; contract grant numbers ISCIII-RETIC RD06/0020/1051, PI09/02483, PI10/01422, PI10/00748, PI13/00285, PI13/00189 2009SGR290 and PI13/00189 2009SQR283; the International Hereditary Cancer Center (Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland) was supported by grants PZ24 KBH_122/PO/2004, Llandspatl – The National University Hospital of Iceland was supported by the Icelandic Association "Walking for Breast Cancer Research" and by the Landspital University Hospital Research Fund; the Interdisciplinary Health Research Internal Team Breast Cancer Susceptibility Study (INHERIT) was supported by the Canadian Institutes of Health Research (CIHR) for the "CIHR Team in Familial Risks of Breast Cancer" program, Canadian Breast Cancer Research Alliance grant 019511 and Ministry of Economic Development, Innovation and Export Trade grant PSR-SIRI-701; the Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study (IOV-HBOCS) is supported by the Ministero della Salute and a "$ > 1,000" Istituto Oncologico Veneto grant; the Portuguese Oncology Institute–Porto Breast Cancer Study (IPOBSC) was supported in part by Liga Portuguesa Contra o Cancro, KcFafib is supported by a grant from the National Research Foundation of South Africa, and the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia; the Mayo Clinic is supported by National Institutes of Health (NIH) grants CA 116167, CA 128978 and CA 176785 through the National Cancer Institute (NCI), an NCI Specialized Program of Research Excellence (SPOR) grant (CA116201), a US Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), a grant from the Breast Cancer Research Foundation, a generous gift from the David F and Margaret T Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation; McGill University Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade; Modifier Study of Quantitative Effects on Disease (MOAIS) was supported by the Ministry of Health of the Czech Republic to Maxyark Memorial Cancer Institute (MHCZ – DRO) (MMC 00209085) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECRAWO, CZ.1.05/2.1.00/03.0101) (to LF), and by Charles University in Prague project UNCE204024 (MZ); Memorial Sloan Kettering Cancer Center (MSKCC) is supported by grants from the Breast Cancer Research Foundation and the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). GEMO Study: National Cancer Genetics Network UNICANCER Genetic Group, France.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HBO2N) coordinating center: Netherlands Cancer Institute, Amsterdam.

Author details
1INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche in Cancérologie de Lyon, Lyon, France. 2Université de Lyon, 69000 Lyon, France. 3Université Lyon 1, 69100 Villeurbanne, France. 4UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive (LBBE), "Biométrie et Biologie Évolutive", Université Claude Bernard Lyon 1, Bâtiment G6, 2, Avenue Claude Bernard, 69622 Villeurbanne, cedex, France. 5Université Grenoble Alpes, UMR 5217, Laboratoire d’Informatique de Grenoble (LIG), équipe-projet Multi-programmation et Ordonnancement sur ressources pour les Applications Interactives de Simulation (MOAIS), 38041 Grenoble, France. 6INRIA Rhône-Alpes, équipe-projet MOAIS, 38334 Saint Ismier, Cedex, France. 7New York for Cancer Genetics, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milan, Italy. 8National Cancer Genetics Network UNICANCER Genetic Group, France.

TheHereditaryBreastandOvarianCancerResearchGroupNetherlands(HBO2N)coordinatingcenter:NetherlandsCancerInstitute,Amsterdam.
Prevention and Special Functions, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda Ospedaliera Universitaria “San Martino” di Genova, IST Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132 Genova, Italy. 48FiorGen Foundation for Pharmacogenomics, Via Luigi Sacconi 6, 50019 Sesto Fiorentino, Italy. 49Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences of Florence, Florence, Italy. 50Department of Molecular Medicine, Sapienza University, Rome, Italy. 51Department of Medical Oncology, Papageiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. 52Molecular Diagnostics Laboratory, INRATES, National Centre for Scientific Research “Demokritos”, Aghia Paraskevi Attiki, Athens, Greece. 53Piana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. 54Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany. 55Clinical Genetics Department, St Michael’s Hospital, Southwell Street, Bristol BS2 8EG, UK. 56North West Thames Regional Genetics Service, Kennedy-Gallton Centre, Harrow, UK. 57Department of Clinical Genetics, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK. 58Menesseys and Cheshire Clinical Genetics Service, Liverpool Women’s NHS Foundation Trust, Flattop 501, South Audley Street, London W1K 6AA, UK. 59Molecular Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHFS Foundation Trust, Manchester, UK. 60Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK. 61Faculty of Medicine, University of Southampton, Southampton University Hospitals NHS Trust, Moat Close, Mainsland Road, Southampton SO16 6YD, UK. 62Institute of Human Genetics, Northern Genetic Service, International Centre for Life, Newcastle upon Tyne Hospitals NHS Trust, Central Parkway, Newcastle upon Tyne NE1 4EP, UK. 63Sheffield Clinical Genetics Service, Sheffield Children’s Hospital, Sheffield, UK. 64Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK. 65Leicestershire Clinical Genetics Service, Department of Clinical Genetics, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester LE1 5SW, UK. 66Oxford Regional Genetics Service, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK. 67Clinical Genetics Service, Guy’s and St Thomas’ NHS Foundation Trust, 7th Floor, Borough Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK. 68North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, Barlby House, 37, Queen Square, London WC1N 3BH, UK. 69Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin, College Green, Dublin 2, Ireland. 70Medical Oncology Service, St James’s Hospital, James’s Street, Dublin 8, Ireland. 71Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrooke’s Hospital, Level 6, Addenbrooke’s Treatment Centre, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK. 72All Wales Medical Genetics Services, University Hospital of Wales, Heath Park, Cardiff CF1 4XW, UK. 73South East Scotland Regional Genetic Service, Western General Hospital, David Brock Building, Crewe Road South, Edinburgh EH4 2XU, UK. 74Centre for Cancer Research & Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK. 75Department of Medical Genetics, Belfast Health and Social Care Trust, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK. 76Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 123 Old Brompton Road, London SW7 3RP, UK. 77Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Block 4, Glasgow G3 8SJ, UK. 78South West Thames Regional Genetics Service, Department of Medical Genetics, St George’s University of London, Cranmer Terrace, London SW17 UR, UK. 79West Midlands Regional Genetics Service, Birmingham Women’s Hospital Healthcare NHS Trust, Mindelsohn Way, Edgbaston, Birmingham B15 2TG, UK. 80Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. 81Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, USA. 82Center for Medical Genetics, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. 83Division of Tumor Genetics, Department of Gynaecology and Obstetrics, University Hospital Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany. 84Center of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institut fur Humangenetik, Bozentrum, Universität Würzburg, Am Hubland, 97074 Würzburg, Germany. 85Center for Hereditary Breast and Ovarian Cancer, Medical Faculty, Center for Integrated Oncology (CIO) Cancer Center Cologne, University Hospital Cologne, Cologne, Germany. 86Center for Molecular Medicine Cologne (CMM), University of Cologne, Robert-Koch-Straße 21, 59031 Cologne, Germany. 87Department of Human Genetics, Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany. 88Institute for Medical Informatics, Statistics and Epidemiology, Medical Faculty, University of Leipzig, Leipzig, Germany. 89Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany. 90Institute of Cell and Molecular Pathology, Centre for Pathology and Forensic and Genetic Medicine, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. 91Institute of Human Genetics, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, 24105 Kiel, Germany. 92Institute of Medical Genetics and Human Genetics, Campus Virchow-Klinikum, Charité Berlin – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. 93German Consortium of Hereditary Breast and Ovarian Cancer (GC-BHOC), Cologne, Germany. 94Institute of Human Genetics, University Hospital Münster, Vessalgasse 12-14, 48149 Münster, Germany. 95Department of Obstetrics and Gynecology, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, D-24105 Kiel, Germany. 96Institute of Medical Genetics and Human Genetics, Campus Virchow-Klinikum, Charité Berlin – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. 97European Group on Tissue Arraying, University Medical Centre Leuven, Leuven, Belgium.


